Northern Trust’s SAB Biotherapeutics SABS Stock Holding History

Northern Trust’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.41M	Buy	362,489 +305,063	+531%	+$1.14M	﹤0.01%	3334
2026 Q1	$220K	Buy	57,426 +41,014	+250%	+$164K	﹤0.01%	3916
2025 Q4	$61.4K	Buy	16,412 +5,025	+44%	+$16.5K	﹤0.01%	4238
2025 Q3	$22.9K	Hold	11,387	–	–	﹤0.01%	4363
2025 Q2	$20K	Hold	11,387	–	–	﹤0.01%	4332
2025 Q1	$15.5K	Hold	11,387	–	–	﹤0.01%	4363
2024 Q4	$43.2K	Buy	+11,387	New	+$37.4K	﹤0.01%	4281
2024 Q1	–	Sell	-4,448	Closed	-$30.6K	–	4471
2023 Q4	$30.6K	Hold	4,448	–	–	﹤0.01%	4317
2023 Q3	$28K	Hold	4,448	–	–	﹤0.01%	4272
2023 Q2	$36.9K	Hold	4,448	–	–	﹤0.01%	4287
2023 Q1	$19.6K	Hold	4,448	–	–	﹤0.01%	4453
2022 Q4	$26.2K	Hold	4,448	–	–	﹤0.01%	4427
2022 Q3	$31K	Hold	4,448	–	–	﹤0.01%	4451
2022 Q2	$64K	Hold	4,448	–	–	﹤0.01%	4333
2022 Q1	$167K	Hold	4,448	–	–	﹤0.01%	4193
2021 Q4	$347K	Buy	+4,448	New	+$417K	﹤0.01%	3949

Other funds holding SABS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust's SABS Position: Q2 2026 in Review

Northern Trust increased its SAB Biotherapeutics (SABS) stake by 531% in Q2 2026, buying an estimated $1.14M and bringing the position to 362,489 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3334.

Northern Trust first reported a position in SABS in Q4 2021 and has held it in 16 quarters since. 46 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

Northern Trust held 362,489 shares of SAB Biotherapeutics worth $1.41M as of Q2 2026.
Northern Trust bought 305,063 SAB Biotherapeutics shares in Q2 2026, an estimated $1.14M.
SAB Biotherapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3334 holding.
Northern Trust first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 16 quarters since.
46 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.